Compounded Semaglutide Linked to Deaths: What You Need to Know
Understanding Compounded Semaglutide Risks
Compounded semaglutide, an active ingredient in popular diabetes and obesity medications, has been reported to cause significant health risks. Novo Nordisk CEO Lars Fruergaard Jorgensen expressed serious concern regarding the compounded version of the medication, noting that they are not FDA-approved.
Health Concerns and Adverse Events
- Linked to over 100 hospitalizations.
- Associated with 10 reported deaths.
- Reported issues include dosing errors and counterfeit products.
The FDA emphasizes that compounded drugs lack rigorous regulatory oversight.
Current Status and Future Implications
With semaglutide still on the FDA's shortage list, the compounded versions may continue to pose a risk. Novo Nordisk is working with the FDA to address these concerns, emphasizing the health of patients as a priority.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.